Boston Scientific Agrees To Pay $4.2Bn For UK Interventional Oncology Firm BTG
A busy year of M&A for Boston Scientific just got busier with a $4.2bn cash offer for UK interventional medicine specialist BTG. Completion is expected by mid-year 2019.
You may also be interested in...
M&A Analysis: 2019 Promises Buoyant Year For M&A
After a record year for medtech M&A deal-making in 2018, Medtech Insight investigates how activity may unfold in the coming year and some of the biggest trends that could hit the industry.
A Chance To Own The Venous Space: BTG Acquires Novate
Complications with inferior vena cava (IVC) filters and subsequent patient-injury lawsuits have made this a tricky space for medical technology innovators, but BTG has not been deterred. The UK company has entered the fray with a technology developed by Novate Medical, and as a bioconvertible product BTG believes it has key advantages compared with other offerings.